Optiflow™
nasal high flow therapy

Proven* respiratory support

*A review of studies comprising the body of NHF evidence found the majority used F&P Optiflow™ systems

Many terms describe NHF, but one stands out: Optiflow NHF therapy

Optiflow NHF therapy is at the forefront of its field, featuring in hundreds of publications and journals such as NEJM and JAMA.

Used as a first-line treatment (pre-intubation and post-extubation), Optiflow may reduce a patient's escalation "up the acuity curve," resulting in better patient outcomes.

 

Clinical practice guidelines for nasal high flow therapy

 


 
Oczkowski et al. Oct. 2021.
European respiratory society 

This guideline provides recommendations for the following populations:
 
  • Acute hypoxemic respiratory failure
  • Post-operative
  • Post-extubation respiratory failure
  • Rest breaks from NIV
  • Acute hypercapnic respiratory failure


Download visual abstract

 
Rochwerg et al. Nov. 2020.
European society of intensive care medicine

This guideline provides recommendations for the following populations:
 
  • Acute hypoxemic respiratory failure
  • Post-operative
  • Post-extubation respiratory failure
  • Peri-intubation



Download visual abstract


 
Discuss Optiflow High Flow Therapy with us



Optiflow nasal high flow in practice

Optiflow™ Nasal High Flow at the Royal Berkshire Hospital (Optiflow Page)

Optiflow NHF therapy across the care continuum

This video shows the introduction of the Airvo 2 device across departments of the Royal Berkshire Hospital in Reading, UK. Hospital clinicians describe the benefits for the hospital and its patient since the Airvo 2 was introduced.
Extubating to Optiflow™ Nasal High Flow therapy

Extubation to Optiflow NHF therapy: Dr Hernández

This video depicts extubation to Optiflow NHF therapy, and is based on the procedure used by Dr. Hernández and his colleagues in the following studies: Hernández et al. JAMA. 2016 (April)1 and Hernández et al. JAMA 2016 (Oct.)2

ROX Index explained

The ROX index can be used to monitor patients and predict the likelihood of NHF therapy success or failure. 

It combines three common measurements: FiO2, SpO2, and respiratory rate, and it is based on two known facts about sicker patients. 1. They require more oxygen. 2. They have a higher respiratory rate.

The index has been validated in a multi-center prospective study conducted with 191 patients with pneumonia.*

Read Online 
Search our FAQs

 


Call us

1800 446 3908 / +1949 453 4000



or get in touch by email

 

Enquire about Optiflow nasal high flow therapy
If you have an enquiry about our products, please provide the following information so a Fisher & Paykel Healthcare representative can contact you. For further details on how this information will be used, see below or go to our privacy statement.
Enter security code:*
 Security code